Our Company

At BioLingus, we believe we can make life better for many people in the world, not just in rich countries, but across the globe.

BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is "inspired by nature" using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery. Our company focusses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.

BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia.

In terms of diabetes, our lead molecules are an oral "biobetter" of liraglutide and exenatide (GLP-1) in type II diabetes.   In addition to that, we are developing a combination product of insulin+GLP1.

We are also exploring the use of low dose IL-2 for early onset juvenile type I diabetes. Low dose IL-2 in animal models has shown to balance Treg and Teff immune cells to reverse or prevent type I diabetes.  Especially in children, having an oral therapy will make a difference.

A second area of interest is immuno-therapy, since sublingual administration  facilitates  targeting the lymphatic system directly.

We have some good data with IL-2 immunotherapy in arthritis, psoriasis, diabetes type 1, peanut allergy and cancer.   We believe that this effect is due to altering the balance of Tregs.

Sublingual administration can increase efficacy and/or reduce side-effects compared to administration by injection.

Our technology can also stabilize proteins and peptides to prevent degradation and this is for use in third world countries by :
- reducing the need for a cold chain
- preventing the risk of infections due to needle handling (e.g. HIV and HCV).

As such, we can “broaden access” for patients in third world countries, which is an important goal for WHO.

Because of the specific properties of our technology, it is applicable to a broad range of molecules, as shown in the diagram below :



July 2016
Yves Decadt, BioLingus CEO explains the innovative technology that takes injectable medicines and transforms them into pills.
Read more

July 2016
Inspiration from nature is transforming how medicines work - EUROPENCEO Interview with Yves Decadt, CEO, BioLingus.
Read more



Yves Decadt

Chief Executive Officer (Belgian)

Before co-founding and becoming CEO of BioLingus, Yves has been CEO of Stragen Pharma SA in Geneva Switzerland, and he was VP Business Development at SkyePharma, working from Basel, Switzerland.
Before that, Yves worked 18 years at Johnson and Johnson, in different roles and countries. Yves joined the global business development group of Johnson & Johnson in 2000, in which he covered a broad spectrum of deal types, from early stage discovery deals to late-stage co-promotion deals. Before that he worked with the BD group of Centocor (which was the biologics groups of JNJ at that time), mainly working on the “next generation” of biologics, such as antibody-drug conjugation, alternative expression systems, improved glycosylation patterns in Mabs and novel protein scaffolds.
Prior to working in business development,Yves had different technical/scientific positions at Janssen Pharmaceutica in Belgium.
Yves Decadt holds a Masters Degree in Bio-Engineering, a Masters Degree in industrial Business Admininistration (both from the University of Ghent in Belgium) and a Masters Degree in Pharmacology and Pharmaceutical Medicine (from the Medical Faculty at the Free Universisty of Brussels). He also followed and executive business program at IMD in Lausanne, Switzerland.

Didier Coquoz

Chief Development Officer (Swiss)

PhD in clinical pharmacology and pharmacist, Dr. Coquoz is a 20+ years seasoned pharma R&D executive (VP R&D and CEO) and serial biotech entrepreneur with experience in North America and Europe.
He has been instrumental in the development/regulatory management from drug candidate up to phase III and registration of close to 30 biologics, monoclonal antibodies, peptides, cell-based therapeties, NCEs, of which 4 reached the market world-wide.
He also has an extensive network in the financing and pharma industries.

Tom Ko

Chief Scientific and Techology Officer (Australian)

Thomas SaiYing Ko is co-founder of BioLingus and heads BioLingus Technology Development P.L. in Hong Kong.
He is a pharmaceutical formulation specialist with 35 years of proven technical and commercial success.
He has special skills in systemic delivery of biologically active peptides or protein for the treatment of chronic diseases without injections. He is also inventor of a number of patents.

Ken Pang

Medical Director (Australian)

Ken (MBBS (Hons), BMedSc, FRACP, PhD) is a practising physician scientist and Associate Professor, Department of Paediatrics, The University of Melbourne.
Clinically, Ken graduated as the valedictorian of his medical school class at Royal Melbourne Hospital in Australia, before completing his specialist training in pediatrics.
Scientifically, Ken completed his PhD at the University of Melbourne in immunology and genomics, and subsequently undertook postdoctoral studies as a Fulbright Scholar in the Department of Molecular and Cellular Biology at Harvard University, where he also completed a Business Development Fellowship within the Office of Technology Development.
Ken's academic output includes 39 peer-reviewed publications that have been cited >8000 times and have appeared in journals such as Science, Immunity, Genome Research, and Molecular Psychiatry.